Wuhan YZY Biopharma Co Receivables

Wuhan YZY Biopharma Co (2496.HK) currently reports a receivables of $40M as of June 2026. That compares with $5M in the prior-year period — up 692.2% year over year. Use the charts on this page to explore Wuhan YZY Biopharma Co's receivables history and peer comparisons.

Wuhan YZY Biopharma Co's receivables increased from $5M to $40M — a 692.2% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Wuhan YZY Biopharma Co reported $40M in receivables as of June 2026. That compares with $5M in the prior-year period — up 692.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $40M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Wuhan YZY Biopharma Co, and consider following 2496.HK for alerts when major investors trade the stock.

Wuhan YZY Biopharma Co is classified in the Healthcare sector. On receivables, it currently shows $40M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 2496.HK with unrelated industries.